IOVA

2.45

9.87% 0.22

Handel nachbörslich: 2.48 0.03 +1.22%

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.23

Offen:

$2.28

24-Stunden-Volumen:

15.21M

Relative Volume:

0.87

Marktkapitalisierung:

$886.54M

Einnahmen:

$32.77M

Nettoeinkommen (Verlust:

$-440.22M

KGV:

-1.4671

EPS:

-1.67

Netto-Cashflow:

$-400.48M

1W Leistung:

-5.04%

1M Leistung:

+31.02%

6M Leistung:

-54.12%

1J Leistung:

-77.19%

1-Tages-Spanne:

$2.25

$2.53

1-Wochen-Bereich:

$1.90

$2.685

52-Wochen-Spanne:

$1.6385

$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (646)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

838

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA Iovance Biotherapeutics Inc	2.45	806.93M	32.77M	-440.22M	-400.48M	-1.67
VRTX Vertex Pharmaceuticals Inc	395.92	99.42B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	561.55	58.99B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	432.52	56.35B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	646.60	39.02B	3.05B	1.28B	-614.78M	19.58
ONC Beone Medicines Ltd Adr	307.51	34.25B	3.81B	-644.79M	-669.77M	-6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-15	Herabstufung	Goldman	Neutral → Sell
2025-05-16	Herabstufung	UBS	Buy → Neutral
2025-05-12	Herabstufung	Truist	Buy → Hold
2025-05-09	Herabstufung	Citizens JMP	Mkt Outperform → Mkt Perform
2024-10-24	Eingeleitet	UBS	Buy
2024-07-29	Herabstufung	Piper Sandler	Overweight → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

01:23 AM

Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance

01:23 AM

Aug 12, 2025

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight - The Malaysian Reserve

Aug 12, 2025

Iovance Soars on Amtagvi Success: What’s Next? - StocksToTrade

Aug 12, 2025

Iovance Biotherapeutics Surges on Promising Study Outcomes - timothysykes.com

Aug 12, 2025

AI Tools Suggest Iovance Biotherapeutics Inc. May Outperform This WeekBuy Alerts With Low Risk Confirmation Noted - 선데이타임즈

Aug 12, 2025

Aug 11, 2025

Published on: 2025-08-12 06:23:53 - beatles.ru

Aug 11, 2025

Aug 09, 2025

Iovance Biotherapeutics' Strategic Turnaround and Regulatory Hurdles: Is the Biotech Buyable at a 64% YTD Decline? - AInvest

Aug 09, 2025

Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results - 富途牛牛

Aug 09, 2025

Iovance Biotherapeutics' Q2 2025 Earnings Miss and Strategic Restructuring: A Turning Point or Deepening Crisis? - AInvest

Aug 09, 2025

Iovance Biotherapeutics Q2 Revenue Misses Estimates, Shares Plummet - AInvest

Aug 09, 2025

Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

Aug 09, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 09, 2025

Measuring Iovance Biotherapeutics Inc.’s beta against major indicesAlgorithmic Prediction of Market Breakouts - Newser

Aug 09, 2025

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 09, 2025

How to escape a deep drawdown in Iovance Biotherapeutics Inc.Free Step-by-Step Trade Signal Implementation - Newser

Aug 09, 2025

Reversal indicators forming on Iovance Biotherapeutics Inc. stockDownside Control Plan With Support Analysis - Newser

Aug 09, 2025

3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - Mitrade

Aug 09, 2025

3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - The Motley Fool

Aug 09, 2025

Key resistance and support levels for Iovance Biotherapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser

Aug 09, 2025

How to escape a deep drawdown in Iovance Biotherapeutics IncPredictive Screener for Daily Trade Watch - Newser

Aug 09, 2025

Is Iovance Biotherapeutics Inc. stock bottoming outReal Time Trade Execution Alert Plan - Newser

Aug 09, 2025

Real time social sentiment graph for Iovance Biotherapeutics Inc.Trading Volume Anomaly Summary and Insight - Newser

Aug 09, 2025

Aug 08, 2025

Why Iovance Biotherapeutics Stock Plummeted Today - AOL.com

Aug 08, 2025

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com

Aug 08, 2025

Iovance falls after missing Q2 expectation - MSN

Aug 08, 2025

Iovance falls after missing Q2 expectation (IOVA:NASDAQ) - Seeking Alpha

Aug 08, 2025

Iovance to Cut Staff by 20% Amid Slow Sales Start for Amtagvi Cell Therapy - AInvest

Aug 08, 2025

Iovance Biotherapeutics Reports Q2 Loss, Stock Down on EMA Filing Withdrawal for Amtagvi - AInvest

Aug 08, 2025

Goldman Sachs Downgrades Iovance Biotherapeutics Amid Lawsuit Turmoil - StocksToTrade

Aug 08, 2025

Building trade automation scripts for Iovance Biotherapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser

Aug 08, 2025

Earnings call transcript: Iovance Biotherapeutics Q2 2025 misses revenue forecast - Investing.com

Aug 08, 2025

Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening - Benzinga

Aug 08, 2025

Iovance Biotherapeutics Exceeds 100 Patient Milestone with Amtagvi Treatment for Advanced Melanoma, Q2 2025 Sales Reach $54 Million. - AInvest

Aug 08, 2025

Iovance Biotherapeutics shares fall 28.79% premarket after reporting a $111.7 million loss in Q2 2025. - AInvest

Aug 08, 2025

Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption - MSN

Aug 08, 2025

Iovance Biotherapeutics (IOVA): Navigating Cost-Cutting and Global Expansion to Unlock Value in TIL Therapies - AInvest

Aug 08, 2025

Iovance Biotherapeutics: Strategic Restructuring and Amtagvi's Long-Term Potential in Immuno-Oncology - AInvest

Aug 08, 2025